Kevin Kalinsky, MD, remarks on how at ASCO 2024, significant studies in metastatic breast cancer were presented, with a focus on hormone-receptor positive disease. The most anticipated trial was DESTINY-Breast06, which evaluated trastuzumab deruxtecan in patients with HER2-low breast cancer that progressed on endocrine therapy. Results showed improved median progression-free survival, although overall survival data are preliminary. Notably, even patients with HER2-ultralow disease showed some benefit.
Another highlight was the postMONARCH trial, which investigated switching endocrine therapy after initial CDK4/6 inhibition. Results indicated improved progression-free survival with abemaciclib plus fulvestrant, particularly in patients who had been on prior CDK4/6 inhibition for 12 months or longer or who lacked visceral metastasis. These studies provide actionable insights for clinical practice, amid ongoing developments in breast cancer therapy.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASCO 2024: Two Key Highlights in Metastatic Breast Cancer Care - Medscape - Jun 10, 2024.
Comments